| Description | CHPG sodium salt is a selective agonist of mGluR5 and activates the ERK and Akt signaling pathways. CHPG sodium salt can be used in studies about traumatic brain injury. |
| In vitro | After the treatment of SO2 derivatives, CHPG sodium salt (10-500 µM) increases the cell viability and decreases the release of LDH. CHPG sodium salt (0.5 mM) prevents SO2-induced apoptosis and increases the expression of TSG-6 through TSG-6/NF-κB pathway in BV2 cells[1]. |
| In vivo | In Sprague-Dawley male rats, injection of CHPG sodium salt (250 nM) reduces the cerebral lesion volume significantly[2]. |
| molecular weight | 223.59 |
| Molecular formula | C8H7ClNNaO3 |
| CAS | 1303993-73-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 6.0 mg/mL (26.8 mM), Sonication and heating to 80℃ are recommended. DMSO: 90.0 mg/mL (402.5 mM), Sonication is recommended. |
| References | 1. Qiu JL, et al. The selective mGluR5 agonist CHPG attenuates SO 2. Chen T, et al. The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway. Int J Mol Med. 2012 Apr;29(4):630-6. |